MyFinsight
Home
Blog
About
Net increase
(decrease) in cash and cash...
-$2,532,518
(-176.30%↓ Y/Y)
Accounts payable
$782,687
(319.35%↑ Y/Y)
Stock-based compensation
$41,780
(-45.33%↓ Y/Y)
Net cash used in
operating activities
-$2,421,528
(47.64%↑ Y/Y)
Net cash used in
investing activities
-$110,667
Net cash provided by
financing activities
-$323
(-100.00%↓ Y/Y)
Canceled cashflow
$824,467
Interest income
$46,504
(-56.88%↓ Y/Y)
Net loss
-$2,967,063
(25.91%↑ Y/Y)
Purchases of property and
equipment
$110,667
Proceeds from issuance of
common stock from atm...
-$323
Canceled cashflow
$46,504
Prepaid expenses and
other current assets
$166,325
(178.19%↑ Y/Y)
Inventories
$56,643
Other assets
$35,330
Accrued and other
current liabilities
-$20,634
(96.26%↑ Y/Y)
Total selling,
general and...
$2,801,004
Total research and
development
$212,563
(-88.81%↓ Y/Y)
Back
Back
Cash Flow
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)
source: myfinsight.com